Biotechnology & Pharmaceuticals

Overview

India's biotechnology and pharmaceutical sector is a paradox: it saves millions of lives globally by producing affordable generics and vaccines, while simultaneously exploiting vulnerable populations in clinical trials, leaving its own citizens exposed to drug-resistant pathogens, and failing to invest in the fundamental research that would make it a true innovator rather than a manufacturer. The sector contributes roughly 1.5% of India's GDP and is the third largest by volume globally, yet it spends less than 0.5% of revenue on R&D — a fraction of what Western and Chinese pharma companies invest.

This duality is rooted in India's policy choices. The 1970 Patents Act, which recognized process patents but not product patents for pharmaceuticals, created the "generics miracle" by allowing Indian companies to reverse-engineer and mass-produce drugs at a fraction of the cost. The 2005 amendment, required by WTO TRIPS obligations, restored product patents and forced a transition toward innovation — a transition that remains incomplete. Understanding this sector means understanding the tension between access and innovation, between public health and private profit, and between India's global humanitarian role and its domestic failures.

Vaccine Production

India is the world's largest vaccine producer by volume, supplying 60% of global vaccine doses through UNICEF, GAVI, and bilateral agreements. The COVID-19 pandemic magnified both India's manufacturing capacity and its geopolitical vulnerability.

• Serum Institute of India (SII): Founded in 1966 by Cyrus Poonawalla in Pune, SII is the world's largest vaccine manufacturer by volume. It produces 1.5 billion doses annually, including polio, measles, tetanus, and meningitis vaccines. During COVID-19, SII manufactured the Oxford-AstraZeneca vaccine (branded Covishield in India) at massive scale, exporting to 170 countries before the devastating second wave forced export bans. A fire at its facility in January 2021 destroyed critical infrastructure and delayed production.
• Bharat Biotech: A Hyderabad-based company that developed India's indigenous COVID-19 vaccine, Covaxin, in collaboration with the Indian Council of Medical Research (ICMR). Covaxin was the first vaccine developed and manufactured entirely within India. Bharat Biotech also produces vaccines for rotavirus, Japanese encephalitis, and chikungunya.
• Biological E and others: Biological E (Hyderabad) is a major producer of DPT and hepatitis B vaccines. Panacea Biotec, Indian Immunologicals, and Haffkine Institute contribute to the ecosystem. The government has established three "vaccine parks" (Chennai, Pune, Hyderabad) to consolidate manufacturing and R&D.
• COVID-19 lessons: India's vaccine diplomacy ("Vaccine Maitri") initially earned global goodwill but collapsed when domestic demand surged. The crisis exposed dependence on imported raw materials (bioreactor bags, filters, adjuvants), prompting a ₹25,000 crore production-linked incentive (PLI) scheme for active pharmaceutical ingredients (APIs) and vaccines.

Generics Industry

India is the "pharmacy of the world" — the largest supplier of generic medicines globally, accounting for 20% of global generic exports by volume. Indian generics have reduced the cost of HIV/AIDS treatment from $10,000 per patient per year to under $100, saving millions of lives in Africa and Asia.

• The 1970 Patents Act: By recognizing only process patents (not product patents) for pharmaceuticals, the Act allowed Indian companies to legally manufacture patented drugs using alternative processes. This created an industry of "reverse engineers" — companies like Cipla (founded 1935), Ranbaxy (now Sun Pharma), and Dr. Reddy's — that specialized in low-cost production.
• TRIPS and the 2005 amendment: India's WTO commitments required restoring product patents by 2005. The amendment introduced a complex framework: product patents for new drugs, compulsory licensing provisions (used in 2012 for Nexavar, a cancer drug), and pre-grant and post-grant opposition mechanisms. The generics industry has adapted by focusing on complex generics (biosimilars, inhalers, injectables) and acquiring foreign companies.
• API dependence: Despite its dominance in formulations, India imports ~70% of active pharmaceutical ingredients (APIs) and key starting materials (KSMs) from China. The COVID-19 supply chain disruption exposed this vulnerability. The government launched the PLI scheme for APIs and bulk drugs, but rebuilding the API ecosystem will take years.
• Quality concerns: Indian generics have faced repeated quality scandals. The US FDA has banned imports from over 50 Indian facilities due to data integrity violations, contamination, and good manufacturing practice (GMP) failures. These bans damage India's reputation and raise questions about whether the low-cost model inherently compromises quality.

Clinical Trials Regulation

India became a favoured destination for global clinical trials in the 2000s due to its large, treatment-naïve population, diverse genetic pool, English-speaking investigators, and low costs. This boom came with severe ethical costs.

• Ethical scandals: Between 2005 and 2012, over 2,000 deaths occurred in clinical trials, many involving vulnerable populations — tribal communities, orphans, and the mentally ill — who lacked informed consent. The HPV vaccine trials (2009) in Andhra Pradesh and Gujarat, funded by the Bill & Melinda Gates Foundation, were suspended after allegations of coercion and inadequate monitoring.
• New Drugs and Clinical Trials Rules, 2019: These rules streamlined the approval process (single-window clearance, 30-day timelines) while strengthening ethics requirements. Audio-video recording of informed consent for vulnerable participants is now mandatory. Compensation for trial-related injury or death must be provided within a defined timeframe. Post-trial access to successful drugs is required.
• Regulatory gaps: Despite reforms, India lacks a dedicated national clinical trials registry with public access to protocols and results. The Central Drugs Standard Control Organization (CDSCO) remains underfunded and understaffed. Ethics committees often function as rubber stamps, and adverse event reporting is incomplete.

Stem Cell Research

India has emerged as a significant player in stem cell research and therapy, driven by a large patient pool, relatively permissive regulations, and a thriving medical tourism industry. However, the line between legitimate research and unproven "stem cell tourism" is often blurred.

• Regulatory framework: The Indian Council of Medical Research (ICMR) issued the National Guidelines for Stem Cell Research in 2017, updated in 2021. These guidelines classify stem cell therapies into: (1) permitted (hematopoietic stem cell transplants for blood disorders), (2) restricted (clinical trials for other conditions), and (3) prohibited (commercial use of unproven therapies). The National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) oversees approvals.
• Research institutions: The Centre for Cellular and Molecular Biology (CCMB, Hyderabad), National Centre for Biological Sciences (NCBS, Bengaluru), and inStem (Institute for Stem Cell Science and Regenerative Medicine, Bengaluru) are leading research centres. CCMB established India's first induced pluripotent stem cell (iPSC) line in 2011.
• Stem cell tourism: Hundreds of clinics across India offer unproven stem cell therapies for autism, cerebral palsy, muscular dystrophy, and anti-aging — conditions for which no evidence exists. These clinics operate in a regulatory grey zone, exploiting desperate patients and damaging India's scientific reputation. The 2021 guidelines explicitly prohibit such commercial use, but enforcement is weak.

Gene Editing (CRISPR)

CRISPR-Cas9, the revolutionary gene-editing technology, has opened possibilities for curing genetic diseases, modifying crops, and even altering human germlines. India has established research capabilities but lags in regulatory clarity and ethical frameworks.

• Research capacity: Indian institutions — CCMB, NCBS, IISc, IITs, and the National Institute of Immunology — have active CRISPR research programs in agriculture (disease-resistant rice, drought-tolerant cotton), livestock, and biomedical applications. India's first CRISPR-edited livestock (a buffalo with increased muscle mass) was developed at the National Dairy Research Institute in 2022.
• Agricultural applications: Gene editing in crops is viewed more favourably than transgenic GMOs because it does not introduce foreign DNA. The Department of Biotechnology (DBT) has funded CRISPR research for rice, wheat, tomato, and banana. However, India's regulatory framework does not clearly distinguish between gene-edited and transgenic organisms, creating uncertainty for commercialization.
• Human germline editing: Following the 2018 He Jiankui scandal in China (where human embryos were edited and implanted), India reinforced its prohibition on germline editing for reproduction. Somatic gene editing (for treating diseases in living patients) is permitted within clinical trial frameworks. The ICMR guidelines (2021) ban reproductive cloning and germline modification.
• Ethical and social concerns: Gene editing raises profound questions about equity — who will access these therapies? — and about the commodification of life. India's caste and class inequalities raise the spectre of genetic "enhancement" becoming another marker of privilege.

Bt Cotton Controversy

The introduction of Bt cotton — genetically modified to produce a toxin from the bacterium Bacillus thuringiensis that kills bollworms — is India's most controversial agricultural biotechnology case. Approved in 2002, Bt cotton now accounts for ~95% of India's cotton acreage, making India the world's largest cotton producer. The story, however, is deeply contested.

• Success narrative: Bt cotton dramatically reduced pesticide use (from 10–12 sprays per season to 2–3), increased yields, and turned India from a net importer to the world's largest cotton exporter. Small farmers benefited from reduced input costs and higher output. By 2014, India produced 40% of global cotton.
• Failure narrative: Critics argue that Bt cotton has increased costs (expensive seeds, secondary pest outbreaks requiring additional pesticides), trapped farmers in debt, and contributed to the epidemic of farmer suicides. The 2006 parliamentary committee on agriculture called for a moratorium on GM crops, citing corporate profiteering and inadequate biosafety testing. The pink bollworm developed resistance to Bt toxins by 2015, forcing farmers to spray pesticides again.
• Regulatory capture: The Genetic Engineering Appraisal Committee (GEAC), India's GM regulator, has been accused of conflict of interest and rushing approvals without adequate independent testing. The 2010 moratorium on Bt brinjal (the first food crop GM approval) was imposed after public outcry, despite GEAC clearance. Bt cotton remains the only GM crop legally cultivated in India.
• Farmer suicides: While multiple studies show no direct causal link between Bt cotton and farmer suicides, the broader context of seed monopolies (Monsanto's royalties, later regulated by government price caps), indebtedness, and climate vulnerability has made Bt cotton a symbol of agrarian distress. The controversy encapsulates the tensions between agricultural biotechnology, corporate power, and farmer autonomy.

Sources